Curium Finalizes Acquisition of Monrol to Expand Production Capabilities
Deal News | Mar 29, 2025 | Globenewswire
Curium Pharma, a global leader in nuclear medicine, has finalized its acquisition of Eczacıbaşı-Monrol Nuclear Products Co., a key industry player based in Istanbul, Turkey. This strategic acquisition enhances Curium's production capacity for lutetium-177 (Lu-177) isotopes, meeting rising global demand and securing supply for its prostate cancer treatments in development. Monrol's complementary R&D capabilities will support Curium's innovative theranostic product pipeline. With Monrol's geographic footprint, including Eastern Europe and the MENA region, Curium expands its PET and SPECT network from 34 to 46 sites, bolstering its integrated production and distribution infrastructure. Curium's International Markets CEO, Chaitanya Tatineni, highlights the transformative impact of merging Curium and Monrol's expertise, promising new opportunities to enhance their diagnostic and therapeutic offerings globally. Meanwhile, Eczacıbaşı's CEO, Emin Fadıllıoğlu, commends Monrol's journey and expresses confidence in its continued growth under Curium's leadership.
Sectors
- Healthcare
- Pharmaceuticals
- Mergers and Acquisitions
Geography
- France – Curium Pharma, the acquiring company, is based in France, and it operates there as part of its global reach in nuclear medicine.
- Turkey – Monrol, the target company, is based in Istanbul, Turkey, and the acquisition underscores the strategic expansion into this region.
- MENA Region – Monrol's presence and distribution in the Middle East and North Africa (MENA) region are significant to Curium's expanded reach in these markets.
- Eastern Europe – The deal includes Monrol's infrastructure in Eastern Europe, enhancing Curium's operational capabilities in this area.
Industry
- Healthcare – The article discusses the acquisition of Monrol by Curium Pharma, both of which operate in the nuclear medicine sector, focusing on radiopharmaceuticals and diagnostics.
- Pharmaceuticals – This acquisition is relevant to the pharmaceutical industry as it involves the production and distribution of radioactive isotopes for therapeutic and diagnostic purposes.
- Mergers and Acquisitions – The article centers around a significant acquisition deal between Curium Pharma and Monrol, highlighting strategic growth through M&A activities.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Curium Pharma | Buyer | Company | A global leader in nuclear medicine, Curium develops, manufactures, and provides world-class radiopharmaceutical products. |
| Eczacba-Monrol Nuclear Products Co. | Target | Company | Based in Istanbul, Monrol specializes in innovative nuclear medicine solutions, offering radioisotopes and radiopharmaceuticals. |
| Emin Fadıllıoğlu | CEO of Eczacba Pharmaceutical and Industrial Investment | Person | Expressed pride and confidence in Monrol's growth and partnership with Curium. |
| Chaitanya Tatineni | CEO of International Markets at Curium | Person | Facilitated the acquisition, emphasizing the combined strengths and future potential. |
| Aydin Kucuk | General Manager of Monrol | Person | Voiced excitement about joining Curium and anticipated collaborative success. |